Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Identification of Pik3ca Mutation as a Genetic Driver of Prostate Cancer That Cooperates with Pten Loss to Accelerate Progression and Castration-Resistant Growth.
Pearson HB, Li J, Meniel VS, Fennell CM, Waring P, Montgomery KG, Rebello RJ, Macpherson AA, Koushyar S, Furic L, Cullinane C, Clarkson RW, Smalley MJ, Simpson KJ, Phesse TJ, Shepherd PR, Humbert PO, Sansom OJ, Phillips WA. Pearson HB, et al. Among authors: furic l. Cancer Discov. 2018 Jun;8(6):764-779. doi: 10.1158/2159-8290.CD-17-0867. Epub 2018 Mar 26. Cancer Discov. 2018. PMID: 29581176 Free article.
CRISP3 expression drives prostate cancer invasion and progression.
Volpert M, Furic L, Hu J, O'Connor AE, Rebello RJ, Keerthikumar S, Evans J, Merriner DJ, Pedersen J, Risbridger GP, McIntyre P, O'Bryan MK. Volpert M, et al. Among authors: furic l. Endocr Relat Cancer. 2020 Jul;27(7):415-430. doi: 10.1530/ERC-20-0092. Endocr Relat Cancer. 2020. PMID: 32357309
Estrogen receptor alpha drives proliferation in PTEN-deficient prostate carcinoma by stimulating survival signaling, MYC expression and altering glucose sensitivity.
Takizawa I, Lawrence MG, Balanathan P, Rebello R, Pearson HB, Garg E, Pedersen J, Pouliot N, Nadon R, Watt MJ, Taylor RA, Humbert P, Topisirovic I, Larsson O, Risbridger GP, Furic L. Takizawa I, et al. Among authors: furic l. Oncotarget. 2015 Jan 20;6(2):604-16. doi: 10.18632/oncotarget.2820. Oncotarget. 2015. PMID: 25436982 Free PMC article.
The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.
Rebello RJ, Kusnadi E, Cameron DP, Pearson HB, Lesmana A, Devlin JR, Drygin D, Clark AK, Porter L, Pedersen J, Sandhu S, Risbridger GP, Pearson RB, Hannan RD, Furic L. Rebello RJ, et al. Among authors: furic l. Clin Cancer Res. 2016 Nov 15;22(22):5539-5552. doi: 10.1158/1078-0432.CCR-16-0124. Epub 2016 Aug 2. Clin Cancer Res. 2016. PMID: 27486174
PIM activity in tumours: A key node of therapy resistance.
Rebello RJ, Huglo AV, Furic L. Rebello RJ, et al. Among authors: furic l. Adv Biol Regul. 2018 Jan;67:163-169. doi: 10.1016/j.jbior.2017.10.010. Epub 2017 Oct 22. Adv Biol Regul. 2018. PMID: 29111105 Review.
Therapeutic Approaches Targeting MYC-Driven Prostate Cancer.
Rebello RJ, Pearson RB, Hannan RD, Furic L. Rebello RJ, et al. Among authors: furic l. Genes (Basel). 2017 Feb 16;8(2):71. doi: 10.3390/genes8020071. Genes (Basel). 2017. PMID: 28212321 Free PMC article. Review.
Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer.
Watt MJ, Clark AK, Selth LA, Haynes VR, Lister N, Rebello R, Porter LH, Niranjan B, Whitby ST, Lo J, Huang C, Schittenhelm RB, Anderson KE, Furic L, Wijayaratne PR, Matzaris M, Montgomery MK, Papargiris M, Norden S, Febbraio M, Risbridger GP, Frydenberg M, Nomura DK, Taylor RA. Watt MJ, et al. Among authors: furic l. Sci Transl Med. 2019 Feb 6;11(478):eaau5758. doi: 10.1126/scitranslmed.aau5758. Sci Transl Med. 2019. PMID: 30728288
CX-5461 Sensitizes DNA Damage Repair-proficient Castrate-resistant Prostate Cancer to PARP Inhibition.
Lawrence MG, Porter LH, Choo N, Pook D, Grummet JP, Pezaro CJ, Sandhu S, Ramm S, Luu J, Bakshi A, Goode DL, Sanij E, Pearson RB, Hannan RD, Simpson KJ, Taylor RA, Risbridger GP, Furic L. Lawrence MG, et al. Among authors: furic l. Mol Cancer Ther. 2021 Nov;20(11):2140-2150. doi: 10.1158/1535-7163.MCT-20-0932. Epub 2021 Aug 19. Mol Cancer Ther. 2021. PMID: 34413130
Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy.
Lawrence MG, Obinata D, Sandhu S, Selth LA, Wong SQ, Porter LH, Lister N, Pook D, Pezaro CJ, Goode DL, Rebello RJ, Clark AK, Papargiris M, Van Gramberg J, Hanson AR, Banks P, Wang H, Niranjan B, Keerthikumar S, Hedwards S, Huglo A, Yang R, Henzler C, Li Y, Lopez-Campos F, Castro E, Toivanen R, Azad A, Bolton D, Goad J, Grummet J, Harewood L, Kourambas J, Lawrentschuk N, Moon D, Murphy DG, Sengupta S, Snow R, Thorne H, Mitchell C, Pedersen J, Clouston D, Norden S, Ryan A, Dehm SM, Tilley WD, Pearson RB, Hannan RD, Frydenberg M, Furic L, Taylor RA, Risbridger GP. Lawrence MG, et al. Among authors: furic l. Eur Urol. 2018 Nov;74(5):562-572. doi: 10.1016/j.eururo.2018.06.020. Epub 2018 Jul 23. Eur Urol. 2018. PMID: 30049486 Free PMC article.
From Sphingosine Kinase to Dihydroceramide Desaturase: A Structure-Activity Relationship (SAR) Study of the Enzyme Inhibitory and Anticancer Activity of 4-((4-(4-Chlorophenyl)thiazol-2-yl)amino)phenol (SKI-II).
Aurelio L, Scullino CV, Pitman MR, Sexton A, Oliver V, Davies L, Rebello RJ, Furic L, Creek DJ, Pitson SM, Flynn BL. Aurelio L, et al. Among authors: furic l. J Med Chem. 2016 Feb 11;59(3):965-84. doi: 10.1021/acs.jmedchem.5b01439. Epub 2016 Feb 3. J Med Chem. 2016. PMID: 26780304
49 results